[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endoscopic-mucosal-resection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endoscopic-mucosal-resection":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,71,105,127,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100617228","endoscopic-full-thickness-suturing-of-mucosal-submucosal-and-perforation-defects-using-su2ura-gi-system-100617228",false,"NCT07315893","Endoscopic Full Thickness Suturing of Mucosal, Submucosal and Perforation Defects Using Su2ura® GI System","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Patient is able to provide informed consent .\n3. Body mass index (BMI) 20-40 kg\u002Fm2\n4. Patient is referred for endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of a gastric neoplastic lesion\n5. Candidate for endoscopic defect closure based on the operating's endoscopist assessment.\n\nExclusion Criteria:\n\n1. Patient with severe comorbidities likely to limit survival to less than 2 years.\n2. Patients with INR\\>1.5\n3. Patients with PLT\\\u003C 150\n4. Patient with known collagen or connective tissue disorders (e.g. scleroderma, marfan syndrome) .\n5. Pregnant women or those intending to become pregnant during the study period\n6. Patient with ascites on physical examination or CT scan.\n7. Patient with varices.\n8. Patient on peritoneal dialysis.\n9. Patient with wound-healing disorders.\n10. Patient with significant coagulation disorders or those requiring anti thrombotic or anticoagulation treatment other than aspirin .\n11. Patient with autoimmune disorder requiring more than 10 mg of corticosteroid daily .\n12. Patients in need of immunomodulatory therapy.\n13. Immunocompromised patients (e.g., HIV\u002FAIDS, organ transplant, chemo- or radiation therapy 6 months prior to recruitment).\n14. Patient in need of concomitant surgical procedures other than those permitted in the protocol.\n15. Non-compliance with the study protocol.\n16. Patient requests to exist the study. -","ALL","18 Years",{"count":18,"type":19},25,"ESTIMATED","INTERVENTIONAL",[22],"NA","The objective of this clinical study is to assess the safety of the Su2ura® GI system when used for endoscopic suturing and soft-tissue approximation in patients referred for endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of gastric neoplastic lesions.\n\nThe main questions it aims to answer are:\n\n1. Percentage of patients with incomplete closure.\n2. Percentage of patients bleeding at closure site within 28 days from procedure.\n3. Percentage of patients with infection at closure site within 28 days from procedure.\n4. Percentage of patients with leakage within 72 hours from procedure.\n5. Serious Adverse Device Effects (SADE) within 28 days from procedure.\n6. Overall rates of Adverse Device Effect within 28 days from procedure.\n\nStudy includes 6 visits: Screening, Baseline\u002FSurgery, Discharge and 4 weeks, 3 months and 6 months post-surgery. The actual point of enrollment for each subject is considered the day of surgery. Total study duration is up to 6.5 months.\n\nThe patient will be admitted to the medical center on the day of the procedure or one day prior for preoperative preparation. Following tissue resection using one of the methods (ESD or EMR), suturing will be performed using the Su2ura® GI system.\n\nPostoperatively, the patient will be transferred to the recovery area and then to the surgical ward for standard monitoring, with an expected one-night postoperative stay and discharge the following day.\n\nStudy follow-up visits will take place 4 weeks, 3 and 6 months post surgery.",[25,26],"Endoscopic Mucosal Resection","Endoscopic Submucosal Dissection (ESD)",[28,29,30],"endoscopic mucosal resection (EMR)","endoscopic submucosal dissection (ESD)","a gastric neoplastic lesion","RECRUITING","2026-01-04",{"date":34,"type":35},"2026-01-07","ACTUAL",{"date":37,"type":35},"2025-08-18",{"date":39,"type":19},"2026-12-31",{"name":41,"class":42},"Anchora Medical","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100588152","randomized-trial-of-cold-emr-compared-to-hybrid-cold-emr-100588152","NCT06937671","Randomized Trial of Cold EMR Compared to Hybrid Cold EMR.","Inclusion Criteria:\n\n* Adult patient (age 18 years or older)\n* Polyp size of at least 20 mm\n* \\- Morphology: Flat or superficially raised polyp morphology (i.e., Paris classification 1s, 0-IIa or 0-IIb, or a combination of the above)\n\nExclusion Criteria:\n\n* Polyps with previous failed resection attempts or polyp recurrence\n* Suspected deep submucosal invasion on endoscopic assessment of surface mucosal pit pattern (Kudo V or NICE 3 pattern) or histologically confirmed malignancy (invasive adenocarcinoma)\n* Polyps with nodules too large (\\>1-1.5cm) for the use of a cold snare\n* Inflammatory bowel disease",{"count":51,"type":19},194,[22],"The goal of this randomized clinical trial is to learn if a combination of hot and cold EMR technique is associated with a lower risk of polyp recurrence without increasing the risk of complication when removing large polyps.\n\nParticipants will undergo EMR and return for a follow-up endoscopy in 3-6 months to check for polyp recurrence.",[55,25],"Polyp of Colon",[57,58,59,60],"EMR","Cold EMR","Hybrid EMR","Endoscopic mucosal resection","2025-11-17",{"date":63,"type":35},"2025-11-20",{"date":65,"type":35},"2025-05-01",{"date":67,"type":19},"2026-12",{"name":69,"class":42},"The Cleveland Clinic",2,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":89,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100422394","endoscopic-resection-of-gastrointestinal-neoplasms-100422394","NCT04780256","Endoscopic Resection of Gastrointestinal Neoplasms","Retrospective Study of Efficacy and Safety of the Endoscopic Removal of Cancerous and Precancerous Lesions of the Upper and Lower Digestive Tract","Inclusion Criteria:\n\n* 18 years or older\n* all patients who have undergone endoscopic resection of an upper or lower digestive tract tumor\n\nExclusion Criteria:\n\n* age under 18\n* inability to provide informed consent","100 Years",{"count":80,"type":19},2000,"OBSERVATIONAL","The study aims to retrospectively investigate the endoscopic resection procedures of cancerous and precancerous lesions of the upper and lower digestive tract in order to evaluate the efficacy and safety outcomes and to compare different resection techniques. In particular, the resection techniques investigated will be mucosectomy, en bloc and piecemeal, endoscopic submucosal dissection (ESD) and its variants, full-thickness resection. The anatomical districts involved will be the esophagus, stomach, duodenum, colon and rectum.",[25,84,85,86,87,88],"Endoscopic Submucosal Dissection","Gastric Neoplasm","Colonic Neoplasms","Esophageal Neoplasms","Duodenal Neoplasms",[90,91,92,93,94],"Endoscopic mucosal resection (EMR)","Endoscopic submucosal dissection (ESD)","Endoscopic full thickness resection (EFTR)","Colorectal ESD","Colorectal EMR","2025-09-30",{"date":97,"type":35},"2025-10-03",{"date":99,"type":35},"2021-03-15",{"date":101,"type":19},"2025-12",{"name":103,"class":104},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":20,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100522083","comparison-of-04-hyaluronic-acid-solution-versus-hydroxyethylamide-solution-in-submucosal-endoscopic-resections-100522083","NCT06077981","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections","Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections of Superficial Malignant Esophageal Neoplasms: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Superficial esophageal adenocarcinoma or squamous cell carcinoma with indication of ESD after discussion in a multidisciplinary oncological board\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Residual or recurrent esophageal lesions\n* Ulcerated esophageal lesions\n* Patients with severe cardiovascular, kidney or liver disease\n* History of hypersensitivity to hyaluronic acid\n* Pregnant or lactating women",{"count":113,"type":19},30,[22],"This is a randomized, single-center clinical trial that will compare the efficacy of two substances used in the submucosal cushion formation stage of endoscopic submucosal resections of early esophageal malignant neoplasms. Such substances are hyaluronic acid in the form of TS-905 Blue Eyeₒ and hydroxyethylamide (Voluven®).",[87,25,117],"Hyaluronic Acid",[87,25,117],"2025-04-29",{"date":65,"type":35},{"date":122,"type":35},"2023-06-19",{"date":124,"type":19},"2026-04-13",{"name":126,"class":42},"Instituto do Cancer do Estado de São Paulo",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":20,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":43},"100363145","esd-for-colorectal-lsl-using-a-selective-strategy---a-prospective-cohort-study-100363145","NCT04008407","ESD for Colorectal LSL Using a Selective Strategy - a Prospective Cohort Study","Endoscopic Submucosal Dissection for Sessile Polyps and Laterally Spreading Lesions of the Colorectum Using a Selective Strategy - a Prospective Cohort Study","COVERT","Inclusion Criteria:\n\n* All patients referred for colorectal resection of large laterally spreading lesions in colon.\n* Can give informed consent to trial participation\n\nExclusion Criteria:\n\n* Previous resection or attempted resection of target adenoma lesion\n* Endoscopic appearance of invasive malignancy\n* Age less than 18 years\n* Pregnancy\n* Active Inflammatory colonic conditions (e.g. inflammatory bowel disease)\n* Use of anticoagulant or antiplatelet agents other than aspirin outside of internationally recognised guidelines\n* American Society of Anesthesiology (ASA) Grade IV-V",{"count":136,"type":19},391,[22],"Colonic Laterally spreading lesions (LSL) =\\> 20mm are at high risk to progress to cancer. Overt stigmata of submucosal invasive cancer (SMIC) has been well characterized and includes ulceration and surface pit pattern changes as per the Kudo classification of type V.\n\nIn a recent report, risk factors for LSL with SMIC and no overt stigmata (i.e. covert SMIC) were described. Resection of these lesions 'en-bloc' can allow for better histological staging and potentially reduce the need for surgical resection.",[140,25],"Colorectal Neoplasm","2025-03-25",{"date":143,"type":35},"2025-03-27",{"date":145,"type":35},"2017-08-14",{"date":147,"type":19},"2028-02",{"name":149,"class":42},"Western Sydney Local Health District",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":20,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":170,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100576924","surveillance-intervals-after-piecemeal-resection-of-non-pedunculated-colorectal-lesions-20mm-100576924","NCT06791616","Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm","Evaluation of Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm: SCARFACE Clinical Trial","Inclusion Criteria:\n\n* Patients with a single non-pedunculated colorectal lesion (NPCL) ≥20 mm that has been resected piecemeal and treated with thermal ablation (using snare tip or argon plasma) at the margins as prophylaxis against recurrence, and who are awaiting the initiation of specific endoscopic follow-up.\n* Complete colonoscopy with adequate or excellent bowel preparation performed within the last 6 months prior to the resection of the index lesion.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Resection performed using a cold snare technique due to the high risk of recurrence.\n* Histology of the lesion showing malignancy: colorectal cancer with submucosal invasion, regardless of invasion depth in microns.\n* Absence of information regarding the grade of dysplasia of the index lesion.\n* Personal history of colorectal cancer.\n* Incomplete endoscopic resection of the index lesion or any other polyps present in the patient.\n* When the endoscopist performing the index colonoscopy expresses doubts about whether the resection was complete.\n* Index lesion with prior attempted resection.\n* Hereditary cancer syndromes (e.g., adenomatous or serrated polyposis syndromes, Lynch syndrome, etc.).\n* Inflammatory bowel disease.\n* Severe comorbidities with reduced life expectancy.\n* Pregnancy.\n* Ongoing cytotoxic treatment or radiotherapy for a malignant disease.","85 Years",{"count":159,"type":19},746,[22],"Intensive endoscopic surveillance following piecemeal resection of non-pedunculated colorectal lesions (NPCL) ≥20 mm is the current standard of care, given the high recurrence rate of these lesions (15-30%). However, most recurrences are detected at 12 months, are small and unifocal, and can be easily resected endoscopically. Furthermore, thermal margin ablation has demonstrated a reduction in recurrence rates to 5-6%, highlighting the need to optimize current surveillance protocols, which are costly, invasive, and impose a significant clinical burden.\n\nThe multicenter SCARFACE clinical trial aims to evaluate whether a reduced surveillance protocol (at 12 and 48 months) is non-inferior to the standard protocol (at 6, 12, and 48 months) in terms of recurrence rates, using a predefined non-inferiority margin. This non-inferiority design aims to determine if the reduced protocol maintains acceptable efficacy while reducing clinical workload and minimizing risks and discomfort associated with intensive follow-up.\n\nPatients will be randomized in a 1:1 ratio into the two surveillance protocols, with an estimated sample size of 746 lesions. The primary objective is to compare the cumulative incidence of recurrence at 12 months. Secondary objectives include characterizing recurrences, assessing complications associated with endoscopic treatments and evaluating the incidence of advanced colorectal lesions. The findings of this study are expected to directly impact clinical guidelines and routine practice, optimizing resource utilization and improving patient quality of life.",[163,164,165,166,25,167,168,169],"Colorectal Neoplasms","Adenoma Colon","Colonic Polyps","Serrated Adenoma","Non-pedunculated Lesions","Thermal Ablation","Recurrence","NOT_YET_RECRUITING","2025-01-19",{"date":173,"type":35},"2025-01-24",{"date":175,"type":19},"2025-03-01",{"date":177,"type":19},"2030-05-31",{"name":179,"class":42},"Asociación Española de Gastroenterología"]